Do the mutations of C1GALT1C1 gene play important roles in the genetic susceptibility to Chinese IgA nephropathy? by Li, Gui-Sen et al.
BioMed  Central
Open Access
Page 1 of 6
(page number not for citation purposes)
BMC Medical Genetics
Research article
Do the mutations of C1GALT1C1 gene play important roles 
in the genetic susceptibility to Chinese IgA nephropathy?
Gui-Sen Li†1,2,3, Guang-Jun Nie†1, Hong Zhang*1, Ji-Cheng LV1, Yan Shen3 
and Hai-Yan Wang1
Address: 1Renal Division, Department of Internal Medicine, Peking University First Hospital, and Peking University Institute of Nephrology, 
Beijing 100034, PR China, 2Renal Division, Sichuan Medical Science Academy & Sichuan Provincial People's Hospital, Chengdu 610072, PR 
China and 3Chinese National Human Genome Center, Beijing 100176, PR China
Email: Gui-Sen Li - guisenli@163.com; Guang-Jun Nie - nienie8888@yahoo.com.cn; Hong Zhang* - hongzh@bjmu.edu.cn; 
Ji-Cheng LV - chenglv@263.net; Yan Shen - sheny@chgb.org.cn; Hai-Yan Wang - why@bjmu.edu.cn
* Corresponding author    †Equal contributors
Abstract
Background: The deficiency of β1,3 galactose in hinge region of IgA1 molecule played a pivotal
role in pathogenesis of IgA nephropathy (IgAN). Cosmc, encoded by C1GALT1C1  gene, was
indispensable to β1,3 galactosylation of IgA1. We designed a serial study to investigate the
relationship between the mutations of C1GALT1C1 gene and the genetic susceptibility to IgAN.
Methods: Nine hundred and thirty-eight subjects, including 661 patients with IgAN and 277
healthy controls were enrolled in the study. Firstly, single nucleotide polymorphisms (SNPs) in the
promoter region of C1GALT1C1 gene were screened. Then the c.-347-190G>A was analyzed by
PCR-restriction fragment length polymorphism (PCR-RFLP) for further case-control association
analysis. Secondly the somatic mutations of DNAs from peripheral blood B lymphocytes were
detected in 15 patients and 7 normal controls.
Results: No significant association was observed between the different alleles or genotypes of c.-
347-190G>A and IgAN. The patients with different genotypes of C1GALT1C1  gene did not
significantly associate with clinical manifestations, including hematuria, proteinuria, and serum
creatinine of patients with IgAN. There was no somatic mutation detected in total 202 clones of
22 individuals.
Conclusion: The c.-347-190G>A polymorphism and the somatic mutation of encoding region of
C1GALT1C1 gene were not significantly related to the genetic susceptibility to IgAN in Northern
Chinese population.
Background
IgA nephropathy (IgAN), which is the most common
glomerulonephritis and a leading cause for end-stage
renal disease (ESRD) worldwide, is characterized by pres-
ence of IgA1 deposit in the glomerular mesangium. In
recent years, aberrant glycosylations of IgA1 molecule in
patients with IgAN were reported [1,2] and were consid-
ered as the most important pathogenic mechanism of
IgAN [3-5]. Previous studies had demonstrated that circu-
lating and glomerular deposited IgA1 in patients with
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IgAN showed deficiency of β1,3 galactose in the hinge
glycopeptides [2,4,6]. The deficiency of hinge-region glyc-
osylation of serum IgA1 showed an increased tendency to
self-aggregation and/or the increased binding to circulat-
ing glycoproteins and enhanced reaction with specific IgG
antibodies directed against IgA1 hinge O-glycans. These
IgA aggregates could escape the clearance by hepatic
receptors for asialoglycoproteins [4]. Others' and our pre-
vious studies demonstrated that IgA1 with deficiency of
hinge-region β1,3 galactose had a higher binding capacity
and stronger biologic effects to cultured human mesangial
cells, leading to accumulation and/or prolonged deposit
of IgA within the mesangium [7-9]. The β1,3 galactose
deficiency of serum IgA1 were closely associated with
renal pathologic phenotypes of IgAN [10]. Therefore, defi-
ciency of hinge-region β1,3 galactosylation of IgA1 mole-
cule might play a pivotal role in the pathogenesis of IgAN.
The mechanisms contributed to aberrant galactosylation
of IgA1 molecule in patients with IgAN were still unclear.
In fact, the core 1 structure Galβ1→3GalNAcα1- Ser/Thr
(T antigen) was synthesized from GalNAcα1-R (Tn anti-
gen) by the action of core 1 β3-galactosyltransferase
(C1β3Gal-T). The coding gene of C1β3Gal-T was
C1GALT1. However, there was no apparent disparity of
C1GALT1 expression among normal controls, non-IgAN
glomerulonephritis, and IgA nephropathy [11]. Further
studies revealed that the C1β3Gal-T activity required
expression of a molecular chaperone designated Cosmc
(core 1β3-Gal-T-specific molecular chaperone) [12].
C1GALT1C1  (OMIM*300611), the coding gene for
Cosmc [12,13], was mapped to chromosome Xq23,
included 3 exons and spanned about 4 kb [12,13]. Muta-
tions of C1GALT1C1  could impressively changed the
enzyme activity of C1β3Gal-T [12,14]. But our previous
study in patients with IgAN revealed that there was only
one mutation (c.393T>A) detected in the coding region of
the C1GALT1C1 gene [15]. The minor allele frequency
(MAF) of c.393T>A was only 6.90% [15]. In additionally,
a previous study had revealed that the conservative
amino-acid substitution (Asp131→Glu) which derived
from the c.393T>A mutation gave normal C1β3Gal-T
activity [14]. However, other two somatic mutations of
C1GALT1C1 gene contributed to the aberrant galactosyla-
tion of Tn syndrome [14]. Malycha et al [16] found that
none of C1GALT1C1 mutations played important roles in
the pathogenesis of IgAN in a rencent study. It was unclear
whether there were any losses of function mutations or
somatic mutations of C1GALT1C1 gene in Chinese IgAN
patients.
We hypothesized that the mutations of C1GALT1C1 gene
could influence its activities in two pathways: mutations
in the promoter region or somatic mutations in the cod-
ing region. To prove the validity of the hypothesis, firstly,
we screened the mutations in the C1GALT1C1 gene in the
promoter region and used a case-control association anal-
ysis to test the relationship of the polymorphisms and the
susceptibility or clinical manifestations of IgAN. Sec-
ondly, somatic mutations of C1GALT1C1  gene were
detected in patients with IgAN.
Methods
Subjects
A total of unrelated 938 northern Chinese were involved
in this study, including 661 patients with IgAN proved by
renal biopsy, and 277 geography-matched healthy con-
trols with normal urine analysis and blood pressure.
Patients with Henoch-schonlein purpura, systemic lupus
erythematosus, and chronic hepatic diseases were
excluded by detailed clinical and laboratory examina-
tions. The mean ages were 31.2 ± 11.4 (patients) and 28.9
± 8.2 (the controls) years. There were 82 female subjects
in the control group and 280 female subjects in the IgAN
patient group. Twenty-two individuals (15 patients who
were recently diagnosed as primary IgAN and 7 controls)
were selected for somatic mutation detection.
Clinical data of patients with IgAN, including age, course
of kidney disease before renal biopsy, as well as blood
pressure and the level of urine protein excretion at the
time of renal biopsy, were collected. At the same time, the
renal function was evaluated, including serum creatinine
and estimated glomerular filtration rate (eGFR) calculated
by the Modification of Diet in Renal Disease abbreviated
equation [17].
The protocol for this study was approved by medical eth-
ics committee of Peking University, and informed written
consents for the study were obtained from all participants.
SNPs Discovery and Genotyping
Genomic DNA of subjects was extracted from the EDTA-
anticoagulated whole blood samples by salting out proce-
dure [18]. The C1GALT1C1 gene was located in the chro-
mosome X. Reference sequence of C1GALT1C1  gene
(OMIM*300611, Version: NC_000023.9) was obtained
from National Center for Biotechnology Information
(NCBI) Gene database http://www.ncbi.nlm.nih.gov/ent
rez. Fifty-eight alleles from chromosome X were screened
in all of the 46 individuals, including 27 unrelated
patients with IgAN (6 females) and 19 unrelated healthy
controls (6 females). The polymerase chain reaction
(PCR) amplification regions included 5' untranslated
regions and the upstream 1 kb from transcriptional initia-
tion site. PCR primers were designed by Primer3 program
[19]. Target sequences were amplified by PCR from 50 ng
genomic DNA in 20 μl of final reaction volume. DNA
sequencing was performed on an ABI PRISM 3700 auto-
mated sequencer. The results of sequencing were analyzedBMC Medical Genetics 2009, 10:101 http://www.biomedcentral.com/1471-2350/10/101
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by Phred/Phrap/Consed suite of software [20]. The SNPs
were described according to the Human Genome Varia-
tion Society (HGVS) nomenclature guidelines [21].
One single nucleotide polymorphism (SNP), c.-347-
190G>A (rs3810744), was detected in the promoter
region of the C1GALT1C1  gene. The MAF of c.-347-
190G>A (rs3810744) was 48.48%. So the SNP was geno-
typed for further association analysis in all 938 subjects by
the standard PCR-restriction fragment length polymor-
phism procedures. The genomic DNA samples were
amplified by PCR using the following primers, forward:
5'-ACGCAGGGGTACATCAGAGAA-3', reverse: 5'-TGAC-
CAGGCTGTTCTAGCTG-3'. The products of 420 base
pairs (bps) were digested by restriction endonuclease
Hpy8I (Fermentas International Inc., Hanover, USA). The
genotypes weren't detected in three controls and one
patient. Forty PCR products were sequenced for accuracy
confirmation of PCR-restriction fragment length poly-
morphism analysis.
B lymphocyte DNA extraction and PCR amplification
Peripheral blood B lymphocytes from 22 participants (15
patients and 7 controls) were isolated by using lym-
phocyte isolation sterile solution (Amersham Biosciences,
Uppsala, Sweden) and CD19 magnetic beads (Dynal Bio-
tech ASA, OSLO, Norway), and then DNA of B lym-
phocytes was extracted by salting out procedure [18]. The
whole coding region was amplified by PCR with follow-
ing primers, forward: 5'-GTTGTTGCAAAGTTCCAGTTTA-
3', reverse: 5'-TTATACCAGTGCCACCAAATTA-3'. The
length of PCR production was 1314 bps. B lymphocyte
DNA (50 ng) was amplified in a final reaction volume of
50 μl, containing 10 pmol of each primer and 2U Pyrobest
DNA polymerase (Takara Biotechnology, Japan). Touch-
down PCR procedure was used as followings: the initial
denaturation at 95°C was followed by 30 cycles of dena-
turation at 95°C for 30 sec, annealing at 68°Cfor 35 sec
(the temperature decrease 0.5°C each circle), and elonga-
tion at 72°C for 100 sec, then 18 cycles of denaturation at
95°C for 30 sec, annealing at 53°C for 35 sec, elongation
at 72°C for 100 sec, finally elongation at 72°C for 7 min.
Gene cloning and somatic mutation detection
PCR products from B lymphocyte DNA of 22 individuals
were subcloned into PGEM-T vector (Promega Corpora-
tion, Madison, WI, USA) after purification and adding
adenine to them. Then ligation productions were trans-
formed to Ecoli Top 10 competent cells and cultured in
Luria-Bertani (LB) solid medium for 14 hours at 37°C.
More than 8 clones per individual were randomly selected
and amplified in LB liquid medium for 14 hours at 37°C.
Plasmids were extracted and digested with PST1 restric-
tion enzyme (Promega Corporation, Madison, WI, USA)
to verify the insertion of PCR productions. Total 202
clones, including 8 to 10 clones per individual, were
directly sequenced to detect somatic mutation.
Statistical Analysis
Observed genotype frequencies in female subjects for all
case and control groups were tested for Hardy-Weinberg
equilibrium using χ2 tests with 1 df. Data were expressed
as percentages or mean ± standard deviation. Pearson's χ2
was used for categorical data. Continuous variables were
tested in each group for normal distribution using the
Kolmogorov-Smirnov test for one variable. Differences of
the means between two groups were tested with Student's
t test. The means among the three groups were compared
by ANOVA analysis. Statistical analysis was performed by
SPSS 10.0 program (SPSS Inc., USA). All tests were two-
sided and a P value of less than 0.05 was considered sta-
tistically significant.
Results
Detection of polymorphisms and association study
One SNP, c.-347-190G>A (rs3810744) was detected in
the promoter region. And then an association analysis was
performed in the cases and controls for the SNP. The fre-
quencies of alleles and genotypes were presented in table
1. The difference in allele frequencies between male and
female controls were not significant (A allele: 0.467 vs.
0.500,  P  = 0.533). No significant associations were
observed between alleles and IgAN, whether in total (P =
0.121), in male (P = 0.684), or in female samples (P =
0.085). The association between genotypes of c.-347-
190G>A and patients with IgAN was significant only in
female population. The frequency of GG/GA genotype
was higher in patients than in controls (0.781 vs. 0.645, P
= 0.033).
C1GALT1C1 gene c.-347-190G>A polymorphism and 
clinical manifestations or prognosis in patients with IgAN
Clinical characteristics of patients with IgAN at the time of
renal biopsy were listed in Table 2. The patients were
divided into two groups according to their genders. When
clinical parameters of two male groups with different gen-
otypes were compared, there was not significant differ-
ence in age, course of disease, incidence of gross
hematuria or high blood pressure, urine protein excretion
Table 1: Distributions of c.-347-190G>A Polymorphism in 
C1GALT1C1 Gene
All Males Females
G A G A GG GA AA G A
Controls 183 170 104 91 28 23 28 79 79
Cases 532 407 210 171 104 114 61 322 236
P value 0.121 0.684 0.033 0.085BMC Medical Genetics 2009, 10:101 http://www.biomedcentral.com/1471-2350/10/101
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in 24 hours, serum creatinine concentration, and serum
levels of IgA. These clinical parameters also did not differ
significantly among the three female groups with different
genotypes.
Somatic mutation detection of B lymphocyte DNA
Although more than 8 clones per individual were
sequenced for the whole coding region, neither new
mutation nor new polymorphism except c.393T>A
(rs17261572) was detected in total 202 clones from B
lymphocyte DNA in 22 individuals (15 patients and 7
controls). The A allele of c.393T>A was only detected in
each clone in two patients with IgAN and one male con-
trol. One of the two patients was male and another one
was a female with AA homozygote. The results were com-
pletely consistent with the sequencing results derived
from the previous genomic DNA.
Discussion
IgA nephropathy, the most common primary glomeru-
lonephritis, was considered as a polygenic and multifacto-
rial disorder. There were extensive evidences suggested the
genetic components were involved in the susceptibility
and progression of IgAN [5,22-24]. The pathogenesis of
IgAN was still indistinct, as far as we knew. Fortunately,
more and more evidences suggested that deficient β1,3
galactosylation of hinge region of IgA1 molecule played
an important role in the pathogenesis of IgAN in recent
years [4,5].
The galactosylation of GalNAcα1-R in hinge region of
IgA1 molecule depended on the activity of C1β3Gal-T.
Intriguingly, patients with IgAN had normal expression of
C1GALT1 gene and decreased expression of C1GALT1C1
gene [11]. Furthermore, diseases resulted from deficiency
of β1,3 galactose, such as Tn syndrome, weren't a result of
decreased expression of C1GALT1 gene, but resulted from
the mutations of C1GALT1C1 gene[14]. These results sug-
gested that it was rather the variants of C1GALT1C1 gene
in influencing the galactosylation of IgA1 hinge-region
than the variants of C1GALT1 gene. It implies that the var-
iants of C1GALT1C1 gene could contribute to susceptibil-
ity of IgAN by influencing β1,3 galactosylation of IgA1
molecule. Our previous study revealed that there was only
one SNP, c.393T>A (rs17261572), in coding region of
C1GALT1C1  [15]. It was a nonsynonymous SNP. The
MAF of c.393T>A was only 0.069. A previous study
revealed that the mutations weren't important for the
European IgAN patients [16]. Were the mutations (includ-
ing somatic mutation) in the promoter region important
in the pathogenesis of IgAN in China? Therefore, we
designed a study to test the hypothesis.
We firstly screened the polymorphisms of C1GALT1C1
gene in promoter region. One SNP, c.-347-190G>A was
detected. And its MAF was 48.48%. Therefore, association
between the c.-347-190G>A polymorphism and IgAN was
explored in a case-control association study in a large pop-
ulation sampled from the Northern Chinese. The associa-
tion analysis revealed that there was no significant
difference of the alleles between the controls and the IgAN
patients in total samples or in two sub-group samples
divided by genders. There was only a weak association
between the genotypes of c.-347-190G>A (GG/GA) and
IgAN detected in female cases. But the positive association
wasn't replicated in male sample simultaneously. The
C1GALT1C1 gene located on chromosome X, so the effect
of polymorphisms would be influenced by the inactivity
of sex chromosome. The positive association might not
demonstrate a truly causal association between the SNP
and IgAN. These results suggested that polymorphisms of
C1GALT1C1 gene might not be related to the susceptibil-
ity of IgAN.
Table 2: General clinical parameters of IgAN patients with different c.-347-190G>A genotypes of C1GALT1C1 gene
Males Females
GA G G G A A A
Age, years 29.6 ± 11.7 30.8 ± 11.7 33.0 ± 10.7 32.6 ± 11.5 31.8 ± 9.9
Courses of diseases, months* 5.0(16.2) 4.0(14.7) 6.0(22.0) 6.0(22.3) 6.0(15.0)
Incidence of gross hematuria, % 27.1 27.8 44.3 44.9 35.1
Incidence of hypertension, % 51.2 48.8 25.0 36.4 33.3
Systolic blood pressure, mmHg 129 ± 20 128 ± 20 117 ± 19 122 ± 23 118 ± 19
Diastolic blood pressure, mmHg 82 ± 15 81 ± 14 74 ± 14 78 ± 14 76 ± 14
Urinary protein excretion, g/day 2.76 ± 3.44 2.14 ± 2.18 2.19 ± 3.26 2.00 ± 2.64 2.11 ± 2.84
Serum creatinine, μmol/l 123.3 ± 95.1 140.6 ± 170.6 89.4 ± 89.9 83.5 ± 40.1 86.0 ± 81.0
eGFR#, ml/min/1.73 m2 67.7 ± 35.0 62.3 ± 29.9 87.1 ± 31.6 86.3 ± 30.3 90.7 ± 35.2
Serum albumin, g/l 37.8 ± 6.9 39.0 ± 7.0 37.4 ± 6.2 38.2 ± 5.3 35.8 ± 7.7
Serum IgA, g/l 2.94 ± 1.27 3.02 ± 1.04 3.00 ± 1.06 3.06 ± 1.35 2.93 ± 1.23
All the parameters were detected at the time of renal biopsy; # eGFR, estimated glomerular filtration rate; * Median (QR).BMC Medical Genetics 2009, 10:101 http://www.biomedcentral.com/1471-2350/10/101
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In present study, we further analyzed the association
between the SNP of C1GALT1C1 gene and clinical param-
eters of IgAN. The results revealed that there was no signif-
icant difference of blood pressure, proteinuria, and renal
function among the IgAN patients with different geno-
types. These data suggested that the genotypes of the
C1GALT1C1 gene did not influence the clinical manifes-
tations of IgAN.
In previous studies of Tn syndrome, three somatic muta-
tions of C1GALT1C1 gene were identified in two patients.
The three somatic mutations, c.202C>T, c.393T>A and
c.454G>A, were all in the coding region of C1GALT1C1
[14]. Except the c.393T>A mutation, both of the other two
somatic mutations could impressively inhibit chaperone
activity and lead to inactivation of C1β3Gal-T, and the
expression of autoimmune Tn antigen on blood cells of
all lineages[14]. Galactosylation deficiency was already
proved in patients with IgAN. Does somatic mutation
exist in C1GALT1C1 gene in patient with IgAN too?
In order to prove this hypothesis, we furthermore per-
formed a somatic mutation screening in the patients with
IgAN. DNAs from B lymphocytes where IgA molecule was
produced were isolated from 22 individuals. And then the
coding region of C1GALT1C1 gene was amplified, cloned
and sequenced. Except the c.393T>A, no other mutations
were detected. The mutation, c.393T>A, was only found in
the patients whose mutations were demonstrated in
genomic DNA by routinely sequencing. Furthermore,
c.393T>A was proved not to be a somatic mutation in
these IgAN patients. The result indicated that the variation
of coding region of C1GALT1C1 gene might be of little
importance in the processing of aberrant glycosylation of
IgA1 molecule in patients with IgAN. Mutations in other
regions of C1GALT1C1 gene, which may influence the gly-
cosylation process of IgA1 molecule, were needed to be
clarified in patients with IgAN. In fact, in a recent study,
Malychaet al [16] detected mutations in whole blood
DNA and in B cell DNA separately in a relative small Euro-
pean sample. They didn't found any important mutations
of C1GALT1C1 gene in patients with IgAN. These results
suggested that the C1GALT1C1 gene might influence the
susceptibility to IgAN by an alternative pathway if it was
important for IgAN.
Conclusion
Our results suggested that the mutation (including
somatic mutation) of C1GALT1C1 gene did not signifi-
cantly contribute to the genetic susceptibility or clinical
manifestations of IgA nephropathy in Chinese popula-
tion.
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